In This Section
Pilot Study of Anti-Oxidant Supplementation with N-Acetyl Cysteine in Stage 0/I Breast Cancer
IRB Protocol #: 12D.396
- Anti-oxidant supplements have been shown to have some general health benefits in some women receiving treatment for breast cancer.
- The purpose of this study is to determine whether or not there are measurable effects on breast tumors in response to a very strong anti-oxidant called N-Acetyl Cysteine (or NAC) in women with stage 0/I breast cancer.
- This treatment is administered to women with breast cancer between their initial biopsy and definitive surgery.
- Up to 35 patients may participate in this study at Thomas Jefferson University.
- An intravenous infusion of NAC will be given each week, and an oral dose of NAC will be taken daily (administered during the period between your biopsy and definite surgery).
- Each infusion is given over approximately one hour and approximately three doses are given over the course of three weeks.
- All treatments are provided free of charge to the participant.
- Females Age > 18
- Women diagnosed with stage 0/I breast cancer by biopsy
- Awaiting surgery, which will either consist of a lumpectomy or mastectomy
- Cannot be pregnant or breastfeeding
- Must not be on any concurrent anti-cancer chemotherapy within the last four weeks
- Must be treated at Thomas Jefferson University Hospital
Michael J. Matthews